Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

A novel design for a dose finding, safety, and drug interaction study of an antiepileptic drug (retigabine) in early clinical development.

Sachdeo R, Partiot A, Biton V, Rosenfeld WE, Nohria V, Tompson D, DeRossett S, Porter RJ.

Int J Clin Pharmacol Ther. 2014 Jun;52(6):509-18. doi: 10.5414/CP202081.

PMID:
24755135
2.

Adjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: Evaluation of efficacy and tolerability.

Brodie MJ, French JA, McDonald SA, Lee WJ, Adams B, Scott A, Nohria V, DeRossett S.

Epilepsy Res. 2014 Jul;108(5):989-94. doi: 10.1016/j.eplepsyres.2014.03.008. Epub 2014 Mar 26.

PMID:
24726452
3.

Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures.

Biton V, Gil-Nagel A, Brodie MJ, Derossett SE, Nohria V.

Epilepsy Res. 2013 Nov;107(1-2):138-45. doi: 10.1016/j.eplepsyres.2013.08.021. Epub 2013 Sep 4.

PMID:
24094693
4.

Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy.

French JA, Abou-Khalil BW, Leroy RF, Yacubian EM, Shin P, Hall S, Mansbach H, Nohria V; RESTORE 1/Study 301 Investigators.

Neurology. 2011 May 3;76(18):1555-63. doi: 10.1212/WNL.0b013e3182194bd3. Epub 2011 Mar 30.

PMID:
21451152
5.

Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy.

Brodie MJ, Lerche H, Gil-Nagel A, Elger C, Hall S, Shin P, Nohria V, Mansbach H; RESTORE 2 Study Group.

Neurology. 2010 Nov 16;75(20):1817-24. doi: 10.1212/WNL.0b013e3181fd6170. Epub 2010 Oct 13.

PMID:
20944074
6.

Clinical development of drugs for epilepsy: a review of approaches in the United States and Europe.

Porter RJ, Baulac M, Nohria V.

Epilepsy Res. 2010 May;89(2-3):163-75. doi: 10.1016/j.eplepsyres.2010.02.005. Epub 2010 Mar 29. Review.

PMID:
20347575
7.

Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies.

Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, Brawanski A, Proescholdt M, Schlaier J, Buchroithner J, Pichler J, Wurm G, Mehdorn M, Strege R, Schuierer G, Villarrubia V, Fellner F, Jansen O, Straube T, Nohria V, Goldbrunner M, Kunst M, Schmaus S, Stauder G, Bogdahn U, Schlingensiepen KH.

Oligonucleotides. 2007 Summer;17(2):201-12.

PMID:
17638524
8.

Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures.

Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM; 205 Study Group.

Neurology. 2007 Apr 10;68(15):1197-204.

PMID:
17420403
9.

Retigabine.

Porter RJ, Nohria V, Rundfeldt C.

Neurotherapeutics. 2007 Jan;4(1):149-54. Review.

PMID:
17199031
10.

Ganaxolone.

Nohria V, Giller E.

Neurotherapeutics. 2007 Jan;4(1):102-5. Review.

PMID:
17199022
11.

Torticollis acquired in late infancy due to a cerebellar gangliocytoma.

Caress JB, Nohria V, Fuchs H, Boustany RM.

Int J Pediatr Otorhinolaryngol. 1996 Jun;36(1):39-44.

PMID:
8803690
12.

Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.

Pilowsky LS, Busatto GF, Taylor M, Costa DC, Sharma T, Sigmundsson T, Ell PJ, Nohria V, Kerwin RW.

Psychopharmacology (Berl). 1996 Mar;124(1-2):148-53.

PMID:
8935810
13.

Erythromycin-induced carbamazepine toxicity: a continuing problem.

Stafstrom CE, Nohria V, Loganbill H, Nahouraii R, Boustany RM, DeLong GR.

Arch Pediatr Adolesc Med. 1995 Jan;149(1):99-101. No abstract available.

PMID:
7827672
14.

Magnetic resonance imaging evidence of hippocampal sclerosis in progression: a case report.

Nohria V, Lee N, Tien RD, Heinz ER, Smith JS, DeLong GR, Skeen MB, Resnick TJ, Crain B, Lewis DV.

Epilepsia. 1994 Nov-Dec;35(6):1332-6.

PMID:
7988529
15.

A splice junction mutation in a new myopathic variant of phosphoglycerate kinase deficiency (PGK North Carolina).

Tsujino S, Tonin P, Shanske S, Nohria V, Boustany RM, Lewis D, Chen YT, DiMauro S.

Ann Neurol. 1994 Mar;35(3):349-53.

PMID:
8122886
16.

The Ch├ędiak-Higashi syndrome: CT and MR findings.

Ballard R, Tien RD, Nohria V, Juel V.

Pediatr Radiol. 1994;24(4):266-7.

PMID:
7800448
17.

Chiari headaches.

Nohria V, Oakes WJ.

Neurology. 1993 Jun;43(6):1272. No abstract available.

PMID:
8170587
18.

EKG abnormalities in pediatric patients with myotonic dystrophy.

Morgenlander JC, Nohria V, Saba Z.

Pediatr Neurol. 1993 Mar-Apr;9(2):124-6.

PMID:
8499041
19.

Chiari I malformation: a review of 43 patients.

Nohria V, Oakes WJ.

Pediatr Neurosurg. 1990-1991;16(4-5):222-7.

PMID:
2135191
20.

The action of dazopride to enhance gastric emptying and block emesis.

Costall B, Domeney AM, Gunning SJ, Kelly ME, Naylor RJ, Nohria V, Owera-Atepo JB, Simpson KM, Tan CC, Tattersall D.

Neuropharmacology. 1987 Jul;26(7A):669-77.

PMID:
3114664
21.

Long-term variation in oxygen consumption rate in preterm infants.

Roberts SB, Murgatroyd PR, Crisp JA, Nohria V, Schlingenseipen KH, Lucas A.

Biol Neonate. 1987;52(1):1-8.

PMID:
3620549
22.

Measurement of carbon dioxide production rate in sick ventilated premature infants.

Lucas A, Nohria V, Roberts SB.

Biol Neonate. 1987;51(3):138-43.

PMID:
3105609
24.

A critical assessment of behavioural test procedures used to analyse dopaminergic and antidopaminergic drugs.

Nohria V.

Methods Find Exp Clin Pharmacol. 1983 Jul-Aug;5(6):357-64. No abstract available.

PMID:
6137599
25.

Behavioural actions of neuroleptics are not reduced by hypophysectomy.

Costall B, Fortune DH, Naylor RJ, Nohria V.

J Pharm Pharmacol. 1982 Sep;34(9):588-90. No abstract available.

PMID:
6127386
26.

Synthesis and dopaminergic properties of some exo- and endo-2-aminobenzonorbornenes designed as rigid analogue of dopamine.

Burn P, Crooks PA, Heatley F, Costall B, Naylor RJ, Nohria V.

J Med Chem. 1982 Apr;25(4):363-8.

PMID:
7200145
27.

Differential effect of benserazide (Ro4-4602) on the concentration of indoleamines in rat pineal and hypothalamus.

Arendt J, Ho AK, Laud C, Marston A, Nohria V, Smith JA, Symons AM.

Br J Pharmacol. 1981 Feb;72(2):257-62.

28.

5,7-Dihydroxy-2-aminotetralin derivatives: synthesis and assessment of dopaminergic and adrenergic actions.

Cannon JG, Brubaker AN, Long JP, Flynn JR, Verimer T, Harnirattisai P, Costall B, Naylor RJ, Nohria V.

J Med Chem. 1981 Feb;24(2):149-53.

PMID:
7205882
29.
30.

Dopamine antagonist properties of atypical neuroleptics may be revealed following mesolimbic denervation.

Nohria V, Costall B, Naylor RJ.

Int Pharmacopsychiatry. 1981;16(1):21-9.

PMID:
6117535
31.

The mesolimbic system, denervation and the climbing response in the mouse.

Costall B, Fortune DH, Naylor RJ, Nohria V.

Eur J Pharmacol. 1980 Aug 29;66(2-3):207-15.

PMID:
6108225
32.

On the ability of N-chloroethyl aporphine derivatives to cause irreversible inhibition of dopamine receptor mechanisms.

Costall B, Fortune DH, Granchelli FE, Law SJ, Naylor RJ, Neumeyer JL, Nohria V.

J Pharm Pharmacol. 1980 Aug;32(8):571-6. No abstract available.

PMID:
6106696
33.

(-)N-(chloroethyl)norapomorphine inhibits striatal dopamine function via irreversible receptor binding.

Costall B, Fortune DH, Law SJ, Naylor RJ, Neumeyer JL, Nohria V.

Nature. 1980 Jun 19;285(5766):571-3.

PMID:
7402299
34.

On the importance of mesolimbic mechanisms for the control of apomorphine induced climbing behaviour in the mouse [proceedings].

Costall B, Naylor RJ, Nohria V.

Br J Pharmacol. 1980 Jan;68(1):175P-176P. No abstract available.

35.

A study of drug action on normal and denervated striatal mechanisms.

Costall B, Fortune DH, Naylor RJ, Nohria V.

Eur J Pharmacol. 1979 Jun 15;56(3):207-16. No abstract available.

PMID:
38970
36.
37.

Hyperactivity response to apomorphine and amphetamine in the mouse: the importance of the nucleus accumbens and caudate-putamen.

Costall B, Naylor RJ, Nohria V.

J Pharm Pharmacol. 1979 Apr;31(4):259-61. No abstract available.

PMID:
36471
38.

Changes in dopamine-dependent motor behaviour caused by propranolol and its isomers.

Costall B, Naylor RJ, Nohria V, Owen RT.

J Pharm Pharmacol. 1978 Oct;30(10):657-60. No abstract available.

PMID:
30826
39.
40.

Supplemental Content

Loading ...
Support Center